A plain-spoken digest of the semaglutide weight-management and metabolic literature — what the trials measured, stated without the marketing.
Semaglutide Prescribed

THE NUMBERS

Semaglutide dosing, as documented in the trials and the approved label.

The escalation schedules, the routes, and the roughly one-week half-life — reported third person from the studies, never as advice.

Before the details

This page reports how semaglutide was dosed in the trials and in its approved labeling. It is a record, not a recommendation: dosing is something a prescriber decides for an individual, and nothing here tells you what to take.

The pattern across studies is a slow build-up. The once-weekly injection starts low and steps up over weeks — this gradual increase is the main tool for limiting the stomach upset that comes with the drug. The daily pill (oral semaglutide) has its own schedule and a strict rule: take it on an empty stomach with only a little water. The drug lasts about a week in the body, which is why one injection covers a whole week and why it takes roughly five weeks to clear after the last dose [11]. Every figure below is tied to a trial protocol or the label.

Semaglutide dose

The defining feature of the semaglutide dose schedule is gradual escalation. For chronic weight management, the subcutaneous regimen documented in the STEP trials and the approved labeling starts at 0.25 mg once weekly for weeks 1-4, then steps to 0.5 mg, 1.0 mg, 1.7 mg, and a 2.4 mg maintenance dose once weekly — the dose used in STEP 1, STEP 4, STEP 5, SELECT and ESSENCE [1][9][3][12]. The escalation exists to limit gastrointestinal effects: a pooled STEP analysis found those events were concentrated around the titration period and were predominantly mild-to-moderate and transient [13].

In type 2 diabetes, the subcutaneous schedule documented in the SUSTAIN program and label initiates at 0.25 mg once weekly, then 0.5 mg, with 1.0 mg as a common maintenance dose; the SUSTAIN-6 cardiovascular trial used 0.5 or 1.0 mg [2], and the FLOW kidney trial used 1.0 mg [6]. These are the doses as studied and labeled, stated in the third person — not a dose anyone should select on their own.

Semaglutide dosage for weight loss

The semaglutide dosage tied to the weight-management evidence on this site is the 2.4 mg once-weekly subcutaneous maintenance dose, reached by the stepwise titration above. That is the dose that produced a mean -14.9% body-weight change at 68 weeks in STEP 1 [1] and sustained loss over two years in STEP 5 [8]. An investigational higher-dose obesity program (STEP UP) studied 7.2 mg once weekly; this site reports it only as an investigational research dose, not an approved one. As with every figure here, this is the documented trial dosage and not a recommendation for any individual.

Semaglutide injection

The semaglutide injection is given subcutaneously (under the skin) once weekly, on the same day each week. Its once-weekly schedule is made possible by the molecule's engineering: resistance to the DPP-4 enzyme plus tight, reversible binding to albumin (a blood carrier protein) extend its half-life to roughly a week [11]. Body-composition work is relevant context for the injectable regimen: a STEP substudy found the weight lost included both fat and a meaningful proportion of lean (muscle) mass [16], which is why protein intake and resistance training are active research topics alongside the injection. Patient-reported injection-site reactions — minor redness, itching or a small bump — are described on the Semaglutide effects page as anecdotal reports, not trial endpoints.

Oral semaglutide

Oral semaglutide is the once-daily tablet form, made possible by co-formulating the peptide with an absorption enhancer called SNAC, which transiently raises the local pH in the stomach so a fraction of the peptide can be absorbed [22]. The documented diabetes schedule is 3 mg daily for 30 days, then 7 mg, then 14 mg daily, taken on an empty stomach about 30 minutes before the first food, drink or other oral medicine, with no more than roughly 120 mL of water [22]. Higher oral doses (25 mg and 50 mg once daily) were studied for obesity in the OASIS and PIONEER PLUS programs. The strict fasted rule matters because oral bioavailability is low — about 0.4-1% even with SNAC — so administration errors substantially reduce the absorbed dose [22]. This is a documented formulation requirement, stated as such.

Half-life and clearance

Semaglutide's elimination half-life is approximately one week — commonly cited as about 165-168 hours — for both the subcutaneous and oral forms, with effectively complete clearance roughly five weeks after the final dose [11]. That long half-life is the structural basis for once-weekly subcutaneous dosing and is conferred by strong, reversible albumin binding via the fatty-acid side chain plus DPP-4 resistance. The clearance arithmetic has a practical downstream: because the drug persists for about five weeks, labeling guidance advises discontinuing well in advance of a planned pregnancy [21]. Stability, per labeling, generally has commercial pens stored refrigerated (2-8 C) before first use and then kept at room temperature for a defined in-use period; this is reported as documented storage information, not a handling instruction for any individual.